LIPC (Hepatic triacylglycerol lipase) variants and mutations
LIPC (also known as Hepatic triacylglycerol lipase) is a human protein-coding gene encoding a hepatic triacylglycerol lipase protein. It hydrolyzes triglycerides and phospholipids in HDL and remnant particles at the liver surface, helping remodel circulating lipoproteins. Loss-of-function variants can raise HDL cholesterol and alter remnant metabolism, with variable effects on atherosclerotic risk. This analysis covers 979 LIPC variants and mutations. Of these, 79% have computational variant effect predictions. Disease context includes hyperlipidemia due to hepatic triglyceride lipase deficiency, age-related macular degeneration, and Hypercholesterolemia. Example LIPC variants include D2E, D2N, and D2V.
Variant analysis overview
- Gene: LIPC
- Protein: Hepatic triacylglycerol lipase
- UniProt accession: P11150
- Organism: Homo sapiens
- Variants analyzed: 979
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 787 unspecified-consequence records; 13 frameshift variants; 76 synonymous variants; 84 missense variants; 9 stop-gained variants; 4 splice-region variants; 4 in-frame deletions; 2 in-frame insertions
- Prediction scores: 771 variants have prediction scores (79% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: hyperlipidemia due to hepatic triglyceride lipase deficiency, age-related macular degeneration, Hypercholesterolemia, metabolic syndrome, type 2 diabetes mellitus, Decreased HDL cholesterol concentration, coronary artery disorder, COVID-19, familial hyperlipidemia, metabolic disease, dry age related macular degeneration, metabolic dysfunction-associated steatotic liver disease.
Protein structure and variant hotspots
- Protein features: 1 domains; 4 post-translational modification sites.
- Structural context: 207 variants have structural context.
- PTM context: 5 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable LIPC variants
Examples include D2E, D2N, D2V, D2Y, T3A, T3I, T3K, T3T. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- D2E (p.Asp2Glu), 1000Genomes rs544198137, ExAC rs544198137, gnomAD rs544198137, REVEL 0.13, CADD 0.08
- D2N (p.Asp2Asn), ExAC rs756169441, TOPMed rs756169441, gnomAD rs756169441
- D2V (p.Asp2Val), rs756402865, ClinGen CA7584664, ClinVar RCV003848298, ExAC rs756402865, REVEL 0.28, CADD 15.10, Uncertain significance, not provided
- D2Y (p.Asp2Tyr), ExAC rs756169441, TOPMed rs756169441, gnomAD rs756169441, REVEL 0.40, CADD 23.10
- T3A (p.Thr3Ala), gnomAD rs1161464498, REVEL 0.27, CADD 0.55
- T3I (p.Thr3Ile), NCI-TCGA Cosmic COSV5442, cosmic curated COSV54424, Variant assessed as somatic; moderate impact.
- T3K (p.Thr3Lys), NCI-TCGA Cosmic COSV5442, Variant assessed as somatic; moderate impact.
- T3T (p.Thr3Thr), rs748972683, gnomAD 15-58432041-A-T, CADD 5.74
- S4C (p.Ser4Cys), cosmic curated COSV54422
- S4G (p.Ser4Gly), TOPMed rs926671529, gnomAD rs926671529, REVEL 0.17, CADD 15.00
- S4R (p.Ser4Arg), rs1893140808, ClinGen CA392794320, ClinVar RCV003695611, Ensembl rs1893140808, REVEL 0.12, CADD 9.23, Uncertain significance, not provided
- S4K (p.Ser4Lys), rs760809626, gnomAD 15-58432040-C-CA, CADD 16.20
- P5R (p.Pro5Arg), ExAC rs770649146, TOPMed rs770649146, gnomAD rs770649146, REVEL 0.15, CADD 0.24
- P5T (p.Pro5Thr), gnomAD 15-58432045-C-A, REVEL 0.13, CADD 0.05
- L6P (p.Leu6Pro), ESP rs139328592, ExAC rs139328592, TOPMed rs139328592, gnomAD rs139328592
- L6Q (p.Leu6Gln), ESP rs139328592, ExAC rs139328592, TOPMed rs139328592, gnomAD rs139328592, REVEL 0.28, CADD 0.10
- L6V (p.Leu6Val), rs1219816687, gnomAD 15-58432047-CCT-C, CADD 15.40
- L6R (p.Leu6Arg), gnomAD 15-58432049-T-G, REVEL 0.53, CADD 0.14
- L6L (p.Leu6Leu), gnomAD 15-58432050-G-T, CADD 1.33
- C7P (p.Cys7Pro), rs769006323, gnomAD 15-58432045-C-CCC, CADD 8.96
- F8L (p.Phe8Leu), Ensembl rs1893141723, REVEL 0.14, CADD 5.35
- S9P (p.Ser9Pro), gnomAD 15-58432057-T-C, REVEL 0.22, CADD 2.51
- S9C (p.Ser9Cys), gnomAD 15-58432058-C-G, REVEL 0.33, CADD 18.50
- L11L (p.Leu11Leu), rs1893141834, gnomAD 15-58432063-C-T, CADD 3.24
- L12V (p.Leu12Val), rs1893141968, ClinGen CA392794365, ClinVar RCV004407374, TOPMed rs1893141968, REVEL 0.24, CADD 10.80, Uncertain significance, not specified
- V13L (p.Val13Leu), gnomAD 15-58432069-G-C, REVEL 0.12, CADD 7.97
- L14S (p.Leu14Ser), NCI-TCGA TCGA novel, TOPMed rs1893142090, gnomAD rs1893142090, REVEL 0.37, CADD 16.40, Variant assessed as somatic; moderate impact.
- L14V (p.Leu14Val), cosmic curated COSV10440
- I16M (p.Ile16Met), TOPMed rs1310906622, gnomAD rs1310906622
- I16N (p.Ile16Asn), ExAC rs745366705, gnomAD rs745366705, REVEL 0.33, CADD 23.30
- I16T (p.Ile16Thr), ExAC rs745366705, gnomAD rs745366705
- I16I (p.Ile16Ile), gnomAD 15-58432080-C-T, CADD 9.67
- F17V (p.Phe17Val), cosmic curated COSV54426
- F17F (p.Phe17Phe), rs959504349, gnomAD 15-58432083-T-C, CADD 7.18
- I18M (p.Ile18Met), TOPMed rs1388586915, gnomAD rs1388586915, REVEL 0.36, CADD 22.60
- I18N (p.Ile18Asn), 1000Genomes rs201654179, REVEL 0.49, CADD 23.30
- Q19K (p.Gln19Lys), ExAC rs772192757
- Q19Q (p.Gln19Gln), rs1595838737, gnomAD 15-58432089-A-G, CADD 2.92
- S20* (p.Ser20Ter), cosmic curated COSV54426
- S20P (p.Ser20Pro), TOPMed rs1391454313, REVEL 0.37, CADD 16.00
- S21T (p.Ser21Thr), ESP rs369107346, ExAC rs369107346, TOPMed rs369107346, gnomAD rs369107346, REVEL 0.20, CADD 12.70, Uncertain significance, not provided
- S21N (p.Ser21Asn), gnomAD 15-58432094-G-A, REVEL 0.17, CADD 13.30
- A22S (p.Ala22Ser), NCI-TCGA Cosmic COSV1001, cosmic curated COSV10013, NCI-TCGA Cosmic COSV5442, Variant assessed as somatic; moderate impact.
- A22T (p.Ala22Thr), cosmic curated COSV54421, REVEL 0.19, CADD 4.31
- A22V (p.Ala22Val), gnomAD 15-58432097-C-T, REVEL 0.17, CADD 8.09
- A22A (p.Ala22Ala), rs760554069, gnomAD 15-58432098-C-A, CADD 3.92
- L23F (p.Leu23Phe), rs145398861, ClinGen CA7584675, ClinVar RCV001119411, ClinVar RCV002556546, REVEL 0.10, CADD 0.48, Conflicting interpretations, not provided; Hyperlipidemia due to hepatic triglyceride lipase deficiency
- G24E (p.Gly24Glu), ExAC rs776432016, TOPMed rs776432016, gnomAD rs776432016, REVEL 0.60, CADD 23.30
- G24V (p.Gly24Val), ExAC rs776432016, TOPMed rs776432016, gnomAD rs776432016, REVEL 0.64, CADD 23.60
- G24* (p.Gly24Ter), gnomAD 15-58432102-G-T, CADD 38.00
- G24G (p.Gly24Gly), gnomAD 15-58432104-A-G, CADD 13.00
- Q25Q (p.Gln25Gln), rs1248669420, gnomAD 15-58432107-A-G, CADD 8.98
- S26I (p.Ser26Ile), TOPMed rs1893143327, gnomAD rs1893143327, REVEL 0.23, CADD 23.30
- S26R (p.Ser26Arg), rs780267766, ClinGen CA7584678, ClinVar RCV003811837, ExAC rs780267766, REVEL 0.25, CADD 17.30, Uncertain significance, not provided
- S26T (p.Ser26Thr), gnomAD 15-58432109-G-C, REVEL 0.18, CADD 19.80
- S26S (p.Ser26Ser), rs780267766, gnomAD 15-58432110-C-T, CADD 10.40
- L27R (p.Leu27Arg), TOPMed rs1893143575
- P29A (p.Pro29Ala), rs1172048757, NCI-TCGA Cosmic COSV1001, cosmic curated COSV10013, TOPMed rs1172048757, REVEL 0.23, CADD 6.13, Variant assessed as somatic; moderate impact.
- P29S (p.Pro29Ser), TOPMed rs1172048757, gnomAD rs1172048757, REVEL 0.19, CADD 8.91
- P29P (p.Pro29Pro), rs1423184794, gnomAD 15-58432119-A-G, CADD 23.00
- E30K (p.Glu30Lys), gnomAD 15-58432120-G-A, REVEL 0.42, CADD 32.00
- E30D (p.Glu30Asp), gnomAD 15-58538334-G-T, REVEL 0.19, CADD 16.60
- P31L (p.Pro31Leu), gnomAD rs1190954809, REVEL 0.17, CADD 15.10
- P31T (p.Pro31Thr), ExAC rs758057124, TOPMed rs758057124, gnomAD rs758057124, REVEL 0.15, CADD 14.30, Uncertain significance, not provided
- P31S (p.Pro31Ser), gnomAD 15-58538335-C-T, REVEL 0.08, CADD 14.10
- F32C (p.Phe32Cys), rs766043850, ClinGen CA7584724, ClinVar RCV002610150, ExAC rs766043850, REVEL 0.31, CADD 21.70, Uncertain significance, not provided
- F32L (p.Phe32Leu), TOPMed rs1893206797
- G33E (p.Gly33Glu), gnomAD rs1475242335, REVEL 0.28, CADD 11.80
- G33R (p.Gly33Arg), cosmic curated COSV54425
- R34K (p.Arg34Lys), Ensembl rs1893207104
- R34I (p.Arg34Ile), gnomAD 15-58538345-G-T, REVEL 0.40, CADD 22.80
- R34R (p.Arg34Arg), rs1227308838, gnomAD 15-58538346-A-G, CADD 8.66
- R35K (p.Arg35Lys), cosmic curated COSV54423
- R35del (p.Arg35del), gnomAD 15-58538341-GGAA-, CADD 15.10
- A36D (p.Ala36Asp), rs1184798854, ClinGen CA392610680, ClinVar RCV003667909, AlphaMissense 0.08, MetaLR 0.51, Uncertain significance, not provided
- A36V (p.Ala36Val), gnomAD rs1184798854, REVEL 0.18, AlphaMissense 0.08, Likely benign, not specified
- A36T (p.Ala36Thr), gnomAD 15-58538350-G-A, REVEL 0.25, CADD 0.80
- Q37E (p.Gln37Glu), cosmic curated COSV10588, TOPMed rs1427358533, gnomAD rs1427358533, REVEL 0.20, CADD 3.88
- Q37R (p.Gln37Arg), ExAC rs751084110, gnomAD rs751084110, REVEL 0.28, CADD 0.00
- Q37* (p.Gln37Ter), gnomAD 15-58538353-C-T, CADD 35.00
- Q37P (p.Gln37Pro), gnomAD 15-58538354-A-C, REVEL 0.34, CADD 0.09
- Q37Q (p.Gln37Gln), rs754483055, gnomAD 15-58538355-A-G, CADD 8.14
- A38S (p.Ala38Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E40K (p.Glu40Lys), NCI-TCGA Cosmic COSV1001, cosmic curated COSV10013, Variant assessed as somatic; moderate impact.
- E40E (p.Glu40Glu), rs150009389, gnomAD 15-58538364-A-G, CADD 5.38
- T41S (p.Thr41Ser), Ensembl rs1893207924
- N42K (p.Asn42Lys), gnomAD rs1458586455, REVEL 0.24, CADD 0.06
- T44M (p.Thr44Met), cosmic curated COSV10515, ExAC rs549763129, TOPMed rs549763129, gnomAD rs549763129, REVEL 0.30, CADD 5.01, Uncertain significance, not provided
- T44R (p.Thr44Arg), ExAC rs549763129, TOPMed rs549763129, gnomAD rs549763129, REVEL 0.29, CADD 1.98
- T44T (p.Thr44Thr), rs755990193, gnomAD 15-58538376-G-A, CADD 0.75
- L45M (p.Leu45Met), gnomAD 15-58538377-C-A, REVEL 0.34, MetaLR 0.70
- L45L (p.Leu45Leu), rs374220111, gnomAD 15-58538377-C-T, CADD 0.46
- H46D (p.His46Asp), cosmic curated COSV10515, REVEL 0.24, CADD 11.60
- H46P (p.His46Pro), TOPMed rs1276070198, gnomAD rs1276070198, Uncertain significance
- H46Q (p.His46Gln), gnomAD rs1893208573, REVEL 0.17, CADD 5.34, Uncertain significance, not provided
- H46R (p.His46Arg), rs1276070198, ClinGen CA392610746, ClinVar RCV004407372, TOPMed rs1276070198, REVEL 0.17, CADD 7.19, Uncertain significance, not specified
- H46H (p.His46His), rs1893208573, gnomAD 15-58538382-T-C, CADD 4.57
- E47Q (p.Glu47Gln), gnomAD 15-58538383-G-C, REVEL 0.27, MetaLR 0.65
- E47V (p.Glu47Val), gnomAD 15-58538384-A-T, REVEL 0.21, MetaLR 0.53
- M48R (p.Met48Arg), rs145223292, ClinGen CA7584731, ClinVar RCV003109038, ClinVar RCV004244574, REVEL 0.23, CADD 2.05, Uncertain significance, not provided; not specified
- M48T (p.Met48Thr), NCI-TCGA Cosmic COSV5442, cosmic curated COSV54422, REVEL 0.19, CADD 0.13, Variant assessed as somatic; moderate impact.
- M48V (p.Met48Val), rs777550023, ClinGen CA7584730, ClinVar RCV002942035, ExAC rs777550023, REVEL 0.13, CADD 5.58, Uncertain significance, not provided
- M48I (p.Met48Ile), gnomAD 15-58538388-G-A, REVEL 0.23, MetaLR 0.13
- K49T (p.Lys49Thr), gnomAD rs1263031616, REVEL 0.23, CADD 8.79
- K49N (p.Lys49Asn), gnomAD 15-58538391-G-C, REVEL 0.27, MetaLR 0.50
- T50A (p.Thr50Ala), Ensembl rs2140905964
- T50I (p.Thr50Ile), gnomAD rs201591235, REVEL 0.20, CADD 15.60
- T50N (p.Thr50Asn), gnomAD 15-58538393-C-A, REVEL 0.53, MetaLR 0.75
- T50T (p.Thr50Thr), rs772238753, gnomAD 15-58538394-C-T, CADD 5.65
- R51T (p.Arg51Thr), NCI-TCGA Cosmic COSV5442, cosmic curated COSV54420, REVEL 0.57, CADD 6.95, Variant assessed as somatic; moderate impact.
- F52* (p.Phe52Ter), gnomAD 15-58538382-T-TGA, CADD 22.50
- F52S (p.Phe52Ser), rs1893209277, gnomAD 15-58538397-AT-A, CADD 26.20
- F52F (p.Phe52Phe), gnomAD 15-58538400-C-T, CADD 6.96
- L53P (p.Leu53Pro), TOPMed rs1174464444, gnomAD rs1174464444, REVEL 0.77, CADD 23.70
- L53L (p.Leu53Leu), rs775758554, gnomAD 15-58538403-G-C, CADD 6.54
- L54I (p.Leu54Ile), NCI-TCGA Cosmic COSV5442, cosmic curated COSV54426, REVEL 0.67, CADD 23.80, Variant assessed as somatic; moderate impact.
- L54F (p.Leu54Phe), gnomAD 15-58538404-C-T, REVEL 0.83, MetaLR 0.89
- F55L (p.Phe55Leu), rs568178076, ClinGen CA7584736, ClinVar RCV003730611, 1000Genomes rs568178076, REVEL 0.42, CADD 21.00, Uncertain significance, not provided
- F55V (p.Phe55Val), cosmic curated COSV54427
- F55W (p.Phe55Trp), rs776917225, gnomAD 15-58538406-CTT-C, CADD 25.30
- F55S (p.Phe55Ser), gnomAD 15-58538408-T-C, REVEL 0.60, MetaLR 0.79
- F55F (p.Phe55Phe), gnomAD 15-58538409-T-C, CADD 7.32
- G56R (p.Gly56Arg), cosmic curated COSV10885, ESP rs376746632, ExAC rs376746632, TOPMed rs376746632, REVEL 0.18, CADD 0.81
- G56G (p.Gly56Gly), rs762421006, gnomAD 15-58538412-A-G, CADD 3.33
- E57K (p.Glu57Lys), NCI-TCGA Cosmic COSV5442, cosmic curated COSV54421, Variant assessed as somatic; moderate impact.
- T58I (p.Thr58Ile), NCI-TCGA Cosmic COSV5442, cosmic curated COSV54427, ExAC rs765770186, TOPMed rs765770186, Variant assessed as somatic; moderate impact.
- T58N (p.Thr58Asn), ExAC rs765770186, TOPMed rs765770186, gnomAD rs765770186, REVEL 0.14, CADD 0.02
- T58S (p.Thr58Ser), ExAC rs765770186, TOPMed rs765770186, gnomAD rs765770186, REVEL 0.13, CADD 0.01
- T58T (p.Thr58Thr), rs773510851, gnomAD 15-58538418-C-G, CADD 0.12
- N59D (p.Asn59Asp), TOPMed rs1038667460, gnomAD rs1038667460
- N59H (p.Asn59His), TOPMed rs1038667460, gnomAD rs1038667460, REVEL 0.26, CADD 13.90
- N59K (p.Asn59Lys), rs751257289, ExAC rs751257289, TOPMed rs751257289, gnomAD rs751257289, REVEL 0.15, CADD 2.69, Variant assessed as somatic; moderate impact.
- N59S (p.Asn59Ser), ExAC rs765991775, TOPMed rs765991775, gnomAD rs765991775, REVEL 0.15, CADD 0.58
- Q60E (p.Gln60Glu), gnomAD rs1398548726, REVEL 0.25, CADD 0.00
- Q60H (p.Gln60His), rs754538725, NCI-TCGA Cosmic COSV5442, cosmic curated COSV54425, ExAC rs754538725, REVEL 0.20, CADD 15.00, Uncertain significance, not specified
- G61A (p.Gly61Ala), TOPMed rs1233508392, REVEL 0.31, CADD 15.10
- G61S (p.Gly61Ser), gnomAD 15-58538425-G-A, REVEL 0.29, MetaLR 0.61
- G61D (p.Gly61Asp), gnomAD 15-58538426-G-A, REVEL 0.32, MetaLR 0.70
- G61G (p.Gly61Gly), gnomAD 15-58538427-C-T, CADD 6.61
- C62Y (p.Cys62Tyr), gnomAD rs1350153104, REVEL 0.90, CADD 24.80
- C62G (p.Cys62Gly), gnomAD 15-58538428-T-G, REVEL 0.85, MetaLR 0.83
- C62C (p.Cys62Cys), rs767028641, gnomAD 15-58538430-T-C, CADD 5.99
- Q63* (p.Gln63Ter), ExAC rs752138731, TOPMed rs752138731, gnomAD rs752138731, CADD 36.00
- Q63H (p.Gln63His), cosmic curated COSV10733, NCI-TCGA TCGA novel, REVEL 0.43, CADD 20.10, Variant assessed as somatic; moderate impact.
- Q63P (p.Gln63Pro), gnomAD 15-58538432-A-C, REVEL 0.65, MetaLR 0.71
- Q63Q (p.Gln63Gln), gnomAD 15-58538433-G-A, CADD 3.83
- R65* (p.Arg65Ter), rs369262181, ClinGen CA7584747, cosmic curated COSV54422, ClinVar RCV001982841, CADD 34.00, Likely pathogenic
- R65L (p.Arg65Leu), ExAC rs777672660, TOPMed rs777672660, gnomAD rs777672660, REVEL 0.20, CADD 0.18
- R65P (p.Arg65Pro), ExAC rs777672660, TOPMed rs777672660, gnomAD rs777672660, REVEL 0.37, CADD 3.31
- R65Q (p.Arg65Gln), rs777672660, NCI-TCGA Cosmic COSV5442, cosmic curated COSV54427, ExAC rs777672660, REVEL 0.17, CADD 0.07, Variant assessed as somatic; moderate impact.
- R65R (p.Arg65Arg), gnomAD 15-58538437-C-A, CADD 4.49
- R65G (p.Arg65Gly), gnomAD 15-58538437-C-G, REVEL 0.17, MetaLR 0.58
- I66M (p.Ile66Met), TOPMed rs1351671396, gnomAD rs1351671396, REVEL 0.23, CADD 2.19
- I66V (p.Ile66Val), rs140029729, ClinGen CA7584749, ClinVar RCV003549359, ESP rs140029729, REVEL 0.10, CADD 0.79, Uncertain significance, not provided
- I66I (p.Ile66Ile), rs1351671396, gnomAD 15-58538442-C-T, CADD 1.25
- N67H (p.Asn67His), gnomAD 15-58538443-A-C, REVEL 0.17, MetaLR 0.47
- N67K (p.Asn67Lys), gnomAD 15-58538444-ATC-A, CADD 21.60
- H68D (p.His68Asp), cosmic curated COSV54425
- H68Y (p.His68Tyr), ExAC rs757045150, gnomAD rs757045150, REVEL 0.34, CADD 19.40
- P69L (p.Pro69Leu), rs143550925, ClinGen CA7584751, cosmic curated COSV10815, ClinVar RCV000293436, REVEL 0.20, CADD 0.83, Uncertain significance, not provided; Hyperlipidemia due to hepatic triglyceride lipase deficiency
- P69P (p.Pro69Pro), rs200127425, gnomAD 15-58538451-G-A, CADD 0.16
- D70G (p.Asp70Gly), rs1313779982, ClinGen CA392610902, ClinVar RCV003441602, TOPMed rs1313779982, REVEL 0.42, CADD 21.50, Uncertain significance, not provided
- T71K (p.Thr71Lys), ExAC rs768938270, TOPMed rs768938270, gnomAD rs768938270, REVEL 0.65, CADD 22.30
- T71M (p.Thr71Met), rs768938270, cosmic curated COSV54423, ExAC rs768938270, TOPMed rs768938270, REVEL 0.62, CADD 22.30, Variant assessed as somatic; moderate impact.
- T71R (p.Thr71Arg), ExAC rs768938270, TOPMed rs768938270, gnomAD rs768938270, REVEL 0.68, CADD 22.40
- T71T (p.Thr71Thr), rs113174258, gnomAD 15-58538457-G-A, CADD 0.04
- L72S (p.Leu72Ser), TOPMed rs1419695477, REVEL 0.68, CADD 24.70
- L72* (p.Leu72Ter), gnomAD 15-58538459-T-A, CADD 37.00
- Q73E (p.Gln73Glu), TOPMed rs1893213288
- Q73H (p.Gln73His), NCI-TCGA Cosmic COSV5442, cosmic curated COSV54422, Variant assessed as somatic; moderate impact.
- Q73R (p.Gln73Arg), NCI-TCGA TCGA novel, REVEL 0.26, CADD 15.10, Variant assessed as somatic; moderate impact.
- Q73K (p.Gln73Lys), gnomAD 15-58538461-C-A, REVEL 0.30, MetaLR 0.58
- Q73* (p.Gln73Ter), gnomAD 15-58538461-C-T, CADD 35.00
- E74D (p.Glu74Asp), ESP rs372176025, TOPMed rs372176025, gnomAD rs372176025, REVEL 0.11, CADD 13.90
- E74Q (p.Glu74Gln), gnomAD rs1893213404, REVEL 0.18, CADD 7.99
- E74A (p.Glu74Ala), gnomAD 15-58538465-A-C, REVEL 0.25, MetaLR 0.37
- E74E (p.Glu74Glu), gnomAD 15-58538466-G-A, CADD 7.00
- C75* (p.Cys75Ter), gnomAD 15-58538469-C-A, CADD 35.00
- C75C (p.Cys75Cys), rs146362585, gnomAD 15-58538469-C-T, CADD 6.33
- G76A (p.Gly76Ala), ExAC rs766788463, TOPMed rs766788463, gnomAD rs766788463, REVEL 0.54, CADD 22.80
Public LIPC analysis runs
- LIPC analysis run — LIPC (979 variants) — completed 2026-08-20